Verona Pharma PLC

Verona Pharma PLC

Verona Pharma PLC

Overview
Date Founded

2005

Headquarters

Alpha House,100 Borough High Street,Suite 21,London, London & South East SE1 1LB

Type of Company

Public

Employees (Worldwide)

25

Industries

Pharmaceuticals
Biotechnology

Company Description

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Executives & Employees

President, Chief Executive Officer & Executive Director

Chief Financial Officer

General Counsel

Chief Medical Officer

Senior Vice President, CMC

Vice President, R&D & Global Project Management

Vice President, Regulatory Affairs

Vice President & Commercial Head

Company Secretary

Co-Founder

Board of Directors

Product Manager at Pfizer GmbH

Co-Founder at ElevateBio LLC

Senior Partner at Novo Ventures 1 A/S

Partner & Portfolio Manager at Abingworth LLP

Partner at OrbiMed Advisors LLC

Venture Partner at Vivo Capital LLC

President, Chief Executive Officer & Executive Director at Verona Pharma PLC

Executive Chairman at PolyTherics Ltd.

Chief Financial Officer & Principal Accounting Officer at Compass Pathways Plc

Head-Copd Center at Sahlgrenska Universitetssjukhuset

Paths to Verona Pharma PLC
Potential Connections via
Relationship Science
You
Verona Pharma PLC
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world.

Recent Transactions
Details Hidden

Verona Pharma PLC issued USD American Depositary Shares

Details Hidden

Verona Pharma PLC raised money in a private placement transaction

Details Hidden

Verona Pharma PLC issued GBP Ordinary Shares

Transaction Advisors
Broker

Advised onVerona Pharma PLC issued GBP Ordinary Shares

Broker

Advised onVerona Pharma PLC issued GBP Ordinary Shares

Auditor

Advised onVerona Pharma PLC issued GBP Ordinary Shares

Legal Advisor

Advised onVerona Pharma PLC issued USD American Depositary Shares

Legal Advisor

Advised onVerona Pharma PLC issued USD American Depositary Shares

Key Stats and Financials As of 2019
Market Capitalization
$367M
Total Enterprise Value
$36.2M
Earnings Per Share
$-3.1
Revenue
$0
Net Profit
$-40.8M
EBITDA
$-51.3M
Total Debt
$1.26M
Total Equity
$44.9M
TEVNet Income
-0.89x
Debt TEV
0.03x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Suppliers
Vernalis Ltd. Wholesale: Consumer Non-Durables/Sundries | Great Abington, United Kingdom

Vernalis Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine. Vernalis also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom.

Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Competitors
GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Viatris, Inc. Pharmaceuticals - Canonsburg, PA

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Verona Pharma PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Verona Pharma PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Verona Pharma PLC.